Market Place
Sourcing Support
Vor Bio Announces $75 Million Private Placement With TCGX
27 Mar 2026 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
26 Aug 2025 //
GLOBENEWSWIRE
Vor Bio reports inducement grants under Nasdaq rule
18 Aug 2025 //
GLOBENEWSWIRE
Telitacicept Hits Phase 3 Goal in Primary Sjögren`s Disease Study
13 Aug 2025 //
GLOBENEWSWIRE
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
17 Jul 2025 //
GLOBENEWSWIRE
Vor Bio explores strategic options to boost shareholder value
08 May 2025 //
GLOBENEWSWIRE
Vor Bio Adds Investor Erez Kalir To Its Board Of Directors
08 Jan 2025 //
GLOBENEWSWIRE
Vor Bio Announces $55.6 Million Private Placement
27 Dec 2024 //
GLOBENEWSWIRE
Vor Bio Reports Q3 2024 Financial Results & Company Update
07 Nov 2024 //
GLOBENEWSWIRE
PureTech`s Vor Bio Announces New Clinical Data
06 Sep 2024 //
BUSINESSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Vor Bio Reports Q2 2024 Results And Company Update
08 Aug 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 Jul 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Jun 2024 //
GLOBENEWSWIRE
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
09 May 2024 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
06 May 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 May 2024 //
GLOBENEWSWIRE
Vor Bio Appoints Fouad Namouni, Cancer Immunotherapy Vet, To Board
02 May 2024 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
01 Apr 2024 //
GLOBENEWSWIRE
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results
20 Mar 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
04 Mar 2024 //
GLOBENEWSWIRE
Vor Bio to Participate in the Oppenheimer 34th Annual Life Sciences Conference
07 Feb 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 Dec 2023 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
27 Nov 2023 //
GLOBENEWSWIRE
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
09 Nov 2023 //
GLOBENEWSWIRE
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
07 Nov 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
03 Nov 2023 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Nov 2023 //
GLOBENEWSWIRE
Multiple Presentations at ASH 2023 Highlight Vor Bio™s Novel eHSC
02 Nov 2023 //
GLOBENEWSWIRE
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
25 Sep 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Vor Reports Second Quarter 2023 Financial Results and Provides Company Update
10 Aug 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
01 Aug 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
11 May 2023 //
GLOBENEWSWIRE
Vor Bio 4Q & 2022 FYR and Provides Company Update
23 Mar 2023 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
21 Feb 2023 //
GLOBENEWSWIRE
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
12 Jan 2023 //
GLOBENEWSWIRE
First AML Patient Successfully Transplanted with Vor Bio’s Trem-cel (VOR33)
07 Dec 2022 //
GLOBENEWSWIRE
Vor Bio Prices Underwritten Offering of Common Stock & Private Placemen
07 Dec 2022 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
22 Nov 2022 //
GLOBENEWSWIRE
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
10 Nov 2022 //
GLOBENEWSWIRE
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing
11 Oct 2022 //
GLOBENEWSWIRE
Vor Bio opts to keep manufacturing operations in-house
29 Sep 2022 //
ENDPTS
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA
28 Sep 2022 //
GLOBENEWSWIRE
Vor Bio Reports Q2 2022 Rusult and Provides Company Update
11 Aug 2022 //
GLOBENEWSWIRE
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells
10 Jun 2022 //
GLOBENEWSWIRE
Vor Bio to Participate in Upcoming Investor Conferences
01 Jun 2022 //
GLOBENEWSWIRE
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
12 May 2022 //
GLOBENEWSWIRE
Vor to Participate in Two Upcoming Investor Conferences
05 May 2022 //
GLOBENEWSWIRE
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
25 Apr 2022 //
GLOBENEWSWIRE
Vor Bio Announces Retirement of Chief Medical Officer
14 Apr 2022 //
GLOBENEWSWIRE
Akron BioProducts and Vor Bio to Collaborate on Nucleases
22 Mar 2022 //
BUSINESSWIRE
Vor Bio Reports Q4 and Full Year 2021 Financial Results; Provides Company Update
14 Mar 2022 //
GLOBENEWSWIRE
Vor to Participate in the 11th Annual SVB Leerink Conference
11 Feb 2022 //
GLOBENEWSWIRE
